Nektar Therapeutics
Stock Forecast, Prediction & Price Target
Nektar Therapeutics Financial Estimates
Nektar Therapeutics Revenue Estimates
Nektar Therapeutics EBITDA Estimates
Nektar Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $101.90M N/A | $92.05M -9.66% | $90.12M -2.09% | Avg: $71.72M Low: $71.72M High: $71.72M avg. -20.41% | Avg: $73.41M Low: $73.41M High: $73.41M avg. 2.36% | Avg: $127.70M Low: $127.70M High: $127.70M avg. 73.93% | Avg: $208.77M Low: $208.77M High: $208.77M avg. 63.48% |
Net Income
% change YoY
| $-523.83M N/A | $-368.19M 29.71% | $-276.05M 25.02% | Avg: $-120.01M Low: $-120.01M High: $-120.01M avg. 56.52% | Avg: $-110.09M Low: $-110.09M High: $-110.09M avg. 8.27% | Avg: $-138.73M Low: $-138.73M High: $-138.73M avg. -26.01% | Avg: $-101.65M Low: $-101.65M High: $-101.65M avg. 26.72% |
EBITDA
% change YoY
| $-453.79M N/A | $-220.53M 51.40% | $-243.10M -10.23% | Avg: $-71.72M Low: $-71.72M High: $-71.72M avg. 70.49% | Avg: $-73.41M Low: $-73.41M High: $-73.41M avg. -2.36% | Avg: $-127.70M Low: $-127.70M High: $-127.70M avg. -73.93% | Avg: $-208.77M Low: $-208.77M High: $-208.77M avg. -63.48% |
EPS
% change YoY
| -$2.86 N/A | -$1.97 31.11% | -$1.45 26.39% | Avg: -$0.63 Low: -$0.63 High: -$0.63 avg. 56.43% | Avg: -$0.58 Low: -$0.58 High: -$0.58 avg. 8.27% | Avg: -$0.73 Low: -$0.73 High: -$0.73 avg. -26.01% | Avg: -$0.54 Low: -$0.54 High: -$0.54 avg. 26.72% |
Operating Expenses
% change YoY
| $523.11M N/A | $310.65M -40.61% | $190.90M -38.54% | Avg: $66.52M Low: $66.52M High: $66.52M avg. -65.15% | Avg: $68.09M Low: $68.09M High: $68.09M avg. 2.36% | Avg: $118.44M Low: $118.44M High: $118.44M avg. 73.93% | Avg: $193.64M Low: $193.64M High: $193.64M avg. 63.48% |
FAQ
What is Nektar Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 16.37% in 2025-2028.
We have gathered data from N/A analysts. Their low estimate is -120.01M, average is -120.01M and high is -120.01M.
What is Nektar Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 29.84% in 2025-2028.
We have gathered data from N/A analysts. Their low revenue estimate is $71.72M, average is $71.72M and high is $71.72M.
What is Nektar Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 16.35% in 2025-2028.
We have gathered data from N/A analysts. Their low earnings per share estimate is -$0.63, average is -$0.63 and high is $-0.63.